SERB Pharmaceuticals has agreed to pay €115 million for exclusive development and commercialization rights to Idefirix® (imlifidase) across Europe and the Middle East and North Africa, acquiring the asset from Hansa Biopharma AB (Nasdaq Stockholm: HNSA). The transaction, announced May 20, 2026, covers the European Union, United Kingdom, Switzerland, Norway, Liechtenstein, and Iceland, in addition to the MENA region.
Deal Structure and Territory
The €115 million headline price buys SERB exclusive rights to both develop and commercialize imlifidase across a combined footprint that spans the EU single market plus four additional European countries and the broader MENA region. The source does not specify a payment schedule — whether upfront, milestone-linked, or a combination — leaving the cash-flow profile of the deal unconfirmed at this stage.
The territorial carve-out is notable for its breadth: by bundling Western European regulatory jurisdictions with the MENA bloc in a single transaction, SERB consolidates what would otherwise require separate regional licensing arrangements.
The Asset: Idefirix® (Imlifidase)
Idefirix® is the brand name for imlifidase, a product originating from Hansa Biopharma's pipeline. The source does not detail the current commercial stage, revenue contribution, or specific clinical indications addressed by the therapy, and no figures on patient population or market size are provided.
The Parties
SERB Pharmaceuticals is the acquirer; Hansa Biopharma AB, listed on Nasdaq Stockholm under the ticker HNSA, is the seller. The announcement was issued jointly by both companies on May 20, 2026, from Brussels. No executives are quoted in the source release, and no advisers or financing arrangements are named.
What the Buy-Side Should Watch
The €115 million price tag is the only hard number disclosed. Until SERB or Hansa Biopharma provides a revenue base, operating cost structure, or development timeline for the European and MENA imlifidase franchise, assigning a multiple to that figure is premature. Investors in HNSA will want to see how Hansa intends to deploy the proceeds — the source is silent on that point.